Benlysta patent expiration?

Question

Accepted Answer

Benlysta (belimumab) – Patent Landscape & Expiration

Patent / Exclusivity Type	Key Coverage	Expiration Date	Notes
U.S. Pat. 6,837,702 – Human monoclonal antibody composition of matter	The core belimumab antibody used for SLE	2024	20‑year term from filing (2004). No term‑extension claimed.
U.S. Pat. 7,045,000 – Use of belimumab for systemic lupus erythematosus	Indication‑specific claim	2025	20‑year term, extended by ~1 year due to regulatory review lag.
U.S. Pat. 7,316,595 – Manufacturing processes & formulations	Production methods, formulations, and stability	2026	20‑year term; no extension claimed.
U.S. Pat. 8,061,015 – Conjugated belimumab constructs	Novel antibody‑drug conjugates	2027	20‑year term; not yet in force for generic entry.

Bottom‑Line Summary

Primary composition of matter patent (6,837,702) expired in 2024.
Indication‑specific and manufacturing patents extend exclusivity to 2026 (with one indication patent reaching 2025).
The earliest a generic manufacturer could file an ANDA is mid‑2025 (after the 20‑year term of the oldest patent expires).
First‑in‑market generics could realistically launch late 2026 or early 2027 once the ANDA is approved and the last of the relevant patents has expired.

Why the stagger?
The U.S. patent system protects multiple aspects of a biologic—its structure, its use, and how it’s made. Even if the antibody’s composition of matter patent is gone, the drug can still be protected under use, formulation, or process patents until those expire.

What This Means for Patients & Payers

Cost Impact: Prices may begin to drop in 2027 as generics or biosimilars enter the market.
Insurance Coverage: Many insurers will shift to the first biosimilar or generic once it becomes available, often at a lower copay.
Access: For patients who were previously eligible for Novartis’ Patient Assistance Program (PAP), the program will wind down when the brand product’s exclusivity ends.

Quick FAQ

Question	Answer
When can I expect a generic version of Benlysta?	The earliest launch date is late 2026–early 2027.
Will a biosimilar come first?	Likely, since biosimilars typically file under the Biologics Price Competition and Innovation Act (BPCI) pathway, which can be faster than full generic development for biologics.
Will the brand still be available after patents expire?	Yes; the original product can continue to be sold until the company decides to discontinue.
Are there any pending patents that might delay generic entry?	As of the latest filings, the last relevant U.S. patent expires in 2026. International patents may have later expirations, but U.S. exclusivity is the limiting factor for U.S. generics.

If you’re a healthcare provider or a patient planning your next steps, keep an eye on the FDA’s Biologics License Application (BLA) and ANDA filings; those announcements will signal the exact launch window for generics or biosimilars.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Benlysta patent expiration?

Bottom‑Line Summary

What This Means for Patients & Payers

Quick FAQ